Ascendis Plans Early Q2 2026 U.S. Launch of Once-Weekly Achondroplasia Therapy with $0 Copays
FDA cleared Ascendis Pharma’s once‐weekly YUVIWEL for children with achondroplasia after Phase 3 data showed annualized growth velocity of 5.9 cm/year versus 4.4 cm/year (1.5 cm treatment difference; p<0.0001) and a 0.3 height Z-score gain at week 52. U.S. launch is scheduled early Q2 2026 with patient copays as low as $0 and affordability programs.
1. FDA Approval and Trial Data
Ascendis Pharma received FDA approval for YUVIWEL, a once-weekly TransCon CNP prodrug for achondroplasia, following three randomized, double-blind, placebo-controlled trials. In the pivotal ApproaCH study, treated children achieved annualized growth velocity of 5.9 cm versus 4.4 cm for placebo (1.5 cm treatment difference; p<0.0001) and a 0.3 improvement in height Z-score at week 52.
2. Commercial Launch and Access Programs
The company plans a U.S. launch in early Q2 2026 pending final packaging, with patient copays as low as $0 through its Ascendis Signature Access Program, which provides reimbursement support, out-of-pocket assistance and training resources. Premium pricing will be announced later this quarter.
3. Market Opportunity and Future Milestones
Ascendis estimates a U.S. pediatric achondroplasia population of about 2,600 (30% on pharmacological treatment) and expects uptake from both switch and treatment-naïve patients. The company holds a Rare Pediatric Disease Priority Review Voucher likely to be sold, aims for European approval by end-2026, plans Q3 completion of its zero-to-two year enrollment study and will initiate adult and hypochondroplasia development programs later in 2026.